Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database
Shih‐Chang Lo, Edy Kornelius, Pei‐Lun Liao, Jing‐Yang Huang, Yi‐Sun Yang, Chien‐Ning Huang
Topics & Concepts
PioglitazoneMedicineMaceHeart failureInternal medicineType 2 diabetesDiabetes mellitusType 2 Diabetes MellitusCardiologyMyocardial infarctionPropensity score matchingEndocrinologyPercutaneous coronary interventionDiabetes Treatment and ManagementHeart Failure Treatment and ManagementCardiovascular Function and Risk Factors